Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.75 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.75 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.75 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.71 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | FABP3 | P05413 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532171 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL21795574 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22533153 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL20767229 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22498713 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531350 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL24802704 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532168 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531357 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532089 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF CORPORATION (JP) | 2026-04-30 | — | — | US | claimed |
| EP-4731305-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2026-04-29 | — | — | EP | claimed |
| US-20260054227-A1 | COMPOSITE MEMBRANE AND METHOD OF MAKING THE SAME | H2MO TECH PTE LTD (SG) | 2026-02-26 | — | — | US | claimed |
| US-12485388-B2 | Composite membrane and method of making the same | H2MO TECHNOLOGY PTE LTD (SG) | 2025-12-02 | — | — | US | claimed |
| EP-4610652-A1 | YAXAB NANOPORE, NANOPORE SYSTEM COMPRISING SAME AND APPLICATIONS THEREOF | Korea Research Institute of Bioscience and Biotechnology (KR) | 2025-09-03 | — | — | EP | claimed |
| US-20250177560-A1 | FUNCTIONALIZED NANOPARTICLES FOR THE CONTAINMENT AND CLEARANCE OF PATHOGENS | THE UNIVERSITY OF CHICAGO (US) | 2025-06-05 | — | — | US | claimed |
| CN-120051687-A | YaxAB nanopores, nanopore systems comprising the YaxAB nanopores and uses thereof | 韩国生命工学研究院 | 2025-05-27 | — | — | CN | claimed |
| WO-2025083024-A1 | IMPROVED FORMULATIONS OF AUTOANTIGEN CONJUGATES | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2025-04-24 | — | — | WO | claimed |
| WO-2025075976-A2 | METHYL-BRANCHED LIPOSOMES FOR SUSTAINED DRUG DELIVERY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-04-10 | — | — | WO | claimed |
| US-20070014841-A1 | Pharmaceutical compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| US-7153541-B2 | Method for inhibiting oxidation of metal sulfide-containing material | U.S. DEPARTMENT OF ENERGY | 2006-12-26 | — | — | US | claimed |
| WO-2006096701-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2006-09-14 | — | — | WO | claimed |
| US-20050220720-A1 | Formulations limiting spread of pulmonary infections | Edwards, David | 2005-10-06 | — | — | US | claimed |
| EP-1536831-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID Biomedical Corporation (CA) | 2005-06-08 | — | — | EP | claimed |
| EP-1531795-A1 | FORMULATIONS LIMITING SPREAD OF PULMONARY INFECTIONS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-05-25 | — | — | EP | claimed |
| US-20050036930-A1 | Method for inhibiting oxidation of metal sulfide-containing material | U.S. DEPARTMENT OF ENERGY | 2005-02-17 | — | — | US | claimed |
| US-20040132652-A1 | Pharmaceutical compositions | SHIRE BIOCHEM INC. (CA) | 2004-07-08 | — | — | US | claimed |
| WO-2004019976-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID BIOMEDICAL CORPORATION (CA) | 2004-03-11 | — | — | WO | claimed |
| WO-2003092654-A1 | FORMULATIONS LIMITING SPREAD OF PULMONARY INFECTIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | SREBF1, SREBF2, FABP1 | P2RY10 4842/4885GPR34 3787/4885GPR174 3668/4885 |
| US-20260054227-A1 | COMPOSITE MEMBRANE AND METHOD OF MAKING THE SAME | AQP1, AQP4, AQP3 | P2RY10 376/4885GPR34 4314/4885GPR174 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.